
    
      A phase 2, multicenter, randomized, parallel Assigned, open-label study to explore the
      safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult
      subjects with chronic genotype 1 HCV infection.

      Approximately 120 HCV genotype 1 subjects without cirrhosis will be enrolled,
      treatment-experienced subjects are â‰¤20%, all subjects will be randomized (1:1) to one of the
      following two treatment groups by IWRS (Medidata Balance): a) DAG181 100 mg/ SOF 400 mg once
      daily for 12 weeks, b) DAG181 200 mg/ SOF 400 mg once daily for 12 weeks. Randomization will
      be stratified by "treatment-naive" or "treatment-experienced".
    
  